18P Trastuzumab in HER2-amplified or overexpressed gallbladder cancer: Experience from an Indian cancer center
نویسندگان
چکیده
The prognosis of advanced gall bladder carcinoma (GBC) remains poor despite the addition newer targeted therapies. HER2 is a potential therapeutic target expressed in up to 20% GBC. We present an analysis or metastatic HER2-amplified overexpressed GBC treated with trastuzumab and chemotherapy from Indian cancer center. Patients immunohistochemical evidence overexpression (IHC 3+) amplification detected FISH, first-line between 2020 2021 were included. Outcome measures objective response rate (ORR), progression-free survival (PFS), overall (OS). Twenty-six patients (age range, 44-71) chemotherapy. Twenty (76.9%) had newly diagnosed disease while six (23.1%) recurred after prior curative treatment. Twenty-four (92.3%) received gemcitabine-cisplatin two (7.7%) gemcitabine-oxaliplatin as Partial was seen 11 (42.3%) 10 (38.5%) stable (objective 42.3%, 80.8%). At median follow-up 15.7 months, PFS 9.7 months (95% CI, 9.3-10) OS 11.9 11.2-12.5). Grade 2 ejection fraction drop 1 patient (3.8%). No adverse events grade 3 more attributable trastuzumab. Trastuzumab added for demonstrated better ORR, compared historical control alone, without any additional toxicities.
منابع مشابه
Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
Trastuzumab has been shown to improve the survival outcomes of HER2 positive breast cancer patients. However, a significant proportion of HER2-positive patients are either inherently resistant or develop resistance to trastuzumab. We assessed the effects of neratinib, an irreversible panHER inhibitor, in a panel of 36 breast cancer cell lines. We further assessed its effects with or without tra...
متن کاملGallbladder cancer: an 'Indian' disease.
The prevalence of gallbladder cancer, the commonest biliary malignancy, shows geographical and racial variations. It is reported to be rare in India. However, the incidence of gallbladder cancer in north and central India is very high--it is the commonest gastrointestinal cancer in women. Even Indian migrants to different countries have a higher risk of having gallbladder cancer as compared to ...
متن کاملAdjuvant trastuzumab in HER2-positive breast cancer.
BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab. METHODS We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive ...
متن کاملHer2 and trastuzumab in breast cancer.
The pace of development of new, clinically relevant information in this area can induce difficulties for clinicians in oncology to become fully aware of and quickly react to these advances. Several recent meetings have reported results that are pertinent to the field of HER2/neu and trastuzumab use in breast cancer. This article summarizes some points on HER2 testing and trastuzumab use that sh...
متن کاملAdjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon, M.D., Ph.D., Wolfgang Eiermann, M.D., Nicholas Robert, M.D., Tadeusz Pienkowski, M.D., Miguel Martin, M.D., Michael Press, M.D., Ph.D., John Mackey, M.D., John Glaspy, M.D., Arlene Chan, M.D., Marek Pawlicki, M.D., Tamas Pinter, M.D., Vicente Valero, M.D., Mei-Ching Liu, M.D., Guido Sauter, M.D., Gunter von Minckwitz, M.D., Frances Visco, J.D., Valerie Bee, M.Sc., Marc Buyse, Sc....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2022
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2022.09.019